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A novel algorithm for analyzing 
drug-drug interactions from 
MEDLINE literature
Yin Lu1, Dan Shen2, Maxwell Pietsch3, Chetan Nagar1, Zayd Fadli4, Hong Huang5,  
Yi-Cheng Tu3 & Feng Cheng1,6
Drug–drug interaction (DDI) is becoming a serious clinical safety issue as the use of multiple 
medications becomes more common. Searching the MEDLINE database for journal articles related 
to DDI produces over 330,000 results. It is impossible to read and summarize these references 
manually. As the volume of biomedical reference in the MEDLINE database continues to expand at 
a rapid pace, automatic identification of DDIs from literature is becoming increasingly important. 
In this article, we present a random-sampling-based statistical algorithm to identify possible DDIs 
and the underlying mechanism from the substances field of MEDLINE records. The substances terms 
are essentially carriers of compound (including protein) information in a MEDLINE record. Four case 
studies on warfarin, ibuprofen, furosemide and sertraline implied that our method was able to rank 
possible DDIs with high accuracy (90.0% for warfarin, 83.3% for ibuprofen, 70.0% for furosemide 
and 100% for sertraline in the top 10% of a list of compounds ranked by p-value). A social network 
analysis of substance terms was also performed to construct networks between proteins and drug 
pairs to elucidate how the two drugs could interact.
Drug-drug interaction (DDI) is typically defined as a change in the effect of a drug when it is taken 
together with another drug. A DDI may involve an increase in the action of either drug, a decrease 
in drug efficacy, a delay in drug absorption rate, or an unexpected harmful side effect. DDI incidence 
increases as the simultaneous use of multiple drugs becomes more common1–3. Centers for Disease 
Control (CDC) reported that the percentage of the U.S. population taking three or more prescription 
drugs increased from 11.8% in 1988–1994 to 20.8% in 2007–2010, and the percentage of people taking 
five or more drugs increased from 4.0% to 10.1% during this same time period4. DDIs are a major cause 
of morbidity and mortality and lead to increased health care costs. DDIs make up nearly 3% of all hospi-
tal admissions5 and 3% to 5% of all inpatient medication errors6. DDIs are difficult to be observed during 
clinical trials because clinical trials do not test for DDIs directly. Serious interactions are often discovered 
after a drug is already on the market for a long time7. Therefore, Identification of possible DDIs is very 
important for drug development and clinical patient care.
The experimental approaches in characterizing DDIs, e.g. in vitro8, in vivo9, and in populo10, are per-
formed at a relatively small scale. Computational methods provide the opportunity to conduct large-scale 
studies on DDIs. Thus far, computational solutions to predict DDIs have consisted of two distinct 
approaches: 1) Similarity-based approaches that measure the similarity of drug information. Previous 
methods were originally designed to infer novel potential targets of drugs based on various type of data, 
such as molecular structures11,12, targets13,14, indications15, side-effects16 and gene expression profiles17. 
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These methods can be used to infer drug interactions. 2) Knowledge-based approaches that predict DDI 
from scientific literature (biomedical abstracts)18–22, an electronic medical record database23 and the FDA 
Adverse Event Reporting System24, where text mining presents a solution to the problem of uncovering 
novel DDIs.
DDIs are frequently reported in clinical and scientific journals. Therefore, literature is the most use-
ful and comprehensive resource for the DDI detection. MEDLINE (Medical Literature Analysis and 
Retrieval System Online) developed by the US National Library of Medicine (NLM), is the most widely 
used database of life sciences and biomedical literature. MEDLINE contains over 24 million entries 
from more than 5,600 journals, with 2,000–4,000 new references being added daily. A MEDLINE search 
for journal articles related to DDI currently produces more than 330,000 results. Though this gigantic 
amount of MEDLINE literature pertaining to DDI offers an unprecedented opportunity for the study 
of drug-drug interaction, it is impossible to identifying DDI information from these references manu-
ally. High throughput, accurate, reliable and user-friendly retrieval of DDI information is in increasing 
demand.
Generally, a MEDLINE record representing one journal article is composed of some fields including 
title of the journal article, author information, journal information, publication type, language, abstract, 
MeSH terms (Medical Subject Headings), and substances. Recently published research has focused on 
information extraction from abstract18–22. In our study we chose the substances field to investigate DDIs 
because the field of MEDLINE records contains a bounty of useful information of compounds and 
proteins. These terms in the substances field are essentially carriers of a documents’ information. The 
Substances terms of MEDLINE records are generally manually indexed by specialized personnel, which 
makes the information more reliable. To our knowledge, no studies have been performed to investigate 
DDIs using substances terms from MEDLINE.
Our strategy was to use a random-sampling-based statistical algorithm to compare the co-occurrence 
of substances with the drug of interest in MEDLINE records containing the keyword “drug interactions” 
and those in records without “drug interactions”. Four case studies on warfarin, ibuprofen, furosemide 
and sertraline implied that our method was able to rank possible DDIs with high accuracy. In addition 
to identifying possible DDIs, the algorithm indicated proteins that may participate in those DDIs. Social 
network analysis was also performed to construct networks between proteins and drug pairs to elucidate 
the possible mechanism of DDIs.
Results
Identification of the drug pairs with DDIs. For ibuprofen, warfarin, furosemide and sertraline, 
there are 500, 2013, 650 and 299 articles with DDI-related MeSH terms in the MEDLINE database, 
respectively. Then, 916, 1364, 932 and 496 candidate substances were identified from the related arti-
cles. The cutoff value of compound pair frequency was set at 3, which means that if the frequency 
of candidate compound was less than 3, the candidate was not considered for further analysis. Our 
random-sampling-based algorithm showed that the co-occurrences of 39, 161, 62, and 29 chemicals 
with the corresponding drugs in articles with drug-interactions were significantly higher than in arti-
cles without drug-interactions (p < 0.1). As shown in Table  1, in the top 10 compounds identified by 
our algorithm, 8, 10, 7, 9 compounds were shown to interact with ibuprofen, warfarin, furosemide and 
sertraline respectively. These four examples show that our algorithm can correctly identify most DDIs.
As shown in Fig. 1, the random sampling step in our algorithm improved accuracy of identification. 
For example, with such a step, our algorithm ranked DDIs with a high accuracy (90% for warfarin, 
83.3% for ibuprofen, 70.0% for furosemide and 100% for sertraline in the top 10% of predicted chemical 
list, shown in black bars in Fig. 1). However, the accuracy (grey bars) was 85.0% for warfarin, 50.0% for 
ibuprofen, 60.0% for furosemide and 50.0% for sertraline in the top 10% of compounds identified by 
co-occurrence without random sampling. The accuracy (white bars) was only 78.3% for warfarin, 42.9% 
for ibuprofen, 50.0% for furosemide and 60.0% for sertraline in the top 10% of compounds identified 
by only frequency. The results prove the effectiveness of the random sampling step to filter irrelevant 
substances terms.
Analysis of the proteins involved DDIs. Understanding the drug-protein-drug interactions is key in 
exploring the action mechanism of DDIs. Besides identifying compound pairs that may interact, we also 
investigated the possible mechanism of DDIs by analyzing the protein information from the substances 
field of MEDLINE records. Statistically significant proteins from the substances terms were identified 
using the same random-sampling-based approach. Significant proteins of ibuprofen, warfarin, furosem-
ide and sertraline were shown in Table 2. PTGS1 protein, CYP2C9 and Aryl Hydrocarbon Hydroxylases 
were identified for ibuprofen. Among them, PTGS1 and CYP2C9 have been shown to be related to DDIs 
involving ibuprofen. Ibuprofen is a substrate of the hepatic cytochrome isoenzyme CYP2C925. Inhibiting 
CYP2C9 by other compounds may lead to increased plasma concentrations of ibuprofen26. In addition, 
the adverse gastrointestinal (GI) effects caused by the nonsteroid anti-inflammatory drugs (NSAID) are 
associated with inhibition of PTGS127. Because ibuprofen exerts similar pharmacologic characteristics 
to other systemic nonsteroidal antiinflammatory drugs (NSAIDs), additive pharmacodynamic effects, 
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including a potential increase for additive adverse gastrointestinal (GI) effects, may be seen if ibuprofen 
is used with other NSAIDs28.
For warfarin, several cytochrome P-450 (CYP) isoenzymes (including CYP3A4, CYP1A2, CYP2D6 
and CYP2C9), steroid 16-alpha-hydroxylase, steroid hydroxylases, aryl hydrocarbon hydroxylases, ala-
nine transaminase, aspartate aminotransferases, PTGS2 and prostaglandin-endoperoxide synthases 
Compouds interacted with ibuprofen Frequency p-value
Fluconazole 7 0
Fluvastatin 3 0
Voriconazole 3 0
Digoxin 6 0
 Lithium 6 0
Captopril 7 0
Aspirin 87 0
Lisinopril 3 0
Warfarin 15 0
Itraconazole 3 2.22E-16
Compouds interacted with warfarin Frequency p-value
Miconazole 22 0
Moxifloxacin 7 0
Methyl salicylate 7 0
Tramadol 7 0
Clarithromycin 7 0
Terbinafine 6 0
Duloxetine 4 0
Fenofibrate 4 0
Tolterodine 3 0
Pitavastatin 3 0
Compouds interacted with furosemide Frequency p-value
Diflunisal 3 0
Clenbuterol 3 0
Probenecid 21 0
Indomethacin 44 0
Fentanyl 3 0
Ceftazidime 3 0
Cephaloridine 7 3.00E-15
Aprotinin 3 1.07E-13
Phenylbutazone 7 1.51E-11
Warfarin 8 2.07E-11
Compouds interacted with sertraline Frequency p-value
linezolid 4 0
Phenytoin 4 0
Ammonium Chloride 3 0
Selegiline 4 0
Carbamazepine 9 0
Methadone 4 1.76E-13
pramipexole 3 3.81E-09
5-Hydroxytryptophan 3 6.59E-09
aripiprazole 5 2.61E-08
1-Naphthylamine 71 5.44E-07
Table 1.  Performance of the identified compounds in a top 10 list of results based on co-occurrence 
with random sampling. Compounds predicted correctly are in italic and bold.
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were identified as statistically significant proteins. Warfarin is stereoselectively metabolized by hepatic 
cytochrome P-450 (CYP) isoenzymes to inactive, hydroxylated metabolites (predominant route) and by 
reductases to reduced metabolites (warfarin alcohols). Inhibiting these cytochrome P-450 (CYP) isoen-
zymes by other compounds may increase or decrease the metabolism of warfarin leading to altered anti-
coagulation effects29. The CYP isoenzymes involved in the metabolism of warfarin include 2C9, 2C19, 
2C8, 2C18, 1A2, and 3A428,30–32. CYP2C9 is the principle enzyme that metabolizes S-warfarin and mod-
ulates the in vivo activity of warfarin. The R-isomer is metabolized by CYP1A2 and CYP3A4, and to a 
lesser extent by CYP2C19.
For furosemide, Thromboxane-A Synthase and Glutathione Transferase were identified. 
Thromboxane-A synthase inhibition can enhance furosemide-induced renal vasodilation33. The activity 
of Glutathione Transferase might be modified after the interaction between furosemide and sulfora-
phane, and this may lead to drug effectiveness alternation34.
For sertraline, several cytochrome P-450 (CYP) isoenzymes (including CYP2D6, CYP2C9, CYP1A2, 
CYP2C19), Mixed Function Oxygenases, Steroid 16-alpha-Hydroxylase, Steroid Hydroxylases, Aryl 
Hydrocarbon Hydroxylases and Receptor, Serotonin, 5-HT1A were identified. In vitro data suggest 
sertraline is a substrate of CYP2B6, CYP2C9, CYP2D6, CYP3A4, and CYP2C1935. Inhibiting these 
cytochrome P-450 (CYP) isoenzymes may increase or decrease the metabolism of sertraline leading 
to increased serum concentrations and possible toxicity36. In addition, antagonizing serotonin (5-HT) 
receptors could oppose the pharmacologic actions of sertraline37. These four case studies show that our 
algorithm can correctly identify most DDI-related proteins.
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Figure 1. Comparison of performance of three methods (ranking DDIs based on frequency: white, 
based on co-occurrence without random sampling filtering: grey, and based on co-occurrence with 
random sampling: black) for ibuprofen, warfarin, furosemide and sertraline. 
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Constructing networks between proteins and drug pairs. In this study, the relationships between 
proteins and drugs were modeled using social network analysis. We inferred that the proteins linking 
drug pairs might take part in the DDIs of the pair. For example, as shown in Fig.  2B, CYP2C9 acted 
as a link between fluoxetine and warfarin. In clinical studies, combining fluoxetine and warfarin may 
further increase the risk of bleeding by inhibiting warfarin’s CYP2C9 metabolism38. Bosentan interacted 
with warfarin with CYP2C9 and CYP3A4 as connective nodes. Coadministration of bosentan 500 mg 
twice daily for 6 days decreases the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and 
R-warfarin (a CYP3A4 substrate) by 29% and 38%, respectively39 The networks will not only show which 
proteins are more important for DDIs but also provide some mechanistic illuminations. The mechanisms 
of DDIs may be classified into pharmacokinetic and pharmacodynamic2. Pharmacokinetic DDIs occur 
when one drug influences the ADMET (absorption, distribution, metabolism, or excretion) of another. 
Pharmacodynamic DDI occur when both drugs act at the same biological target/pathway resulting in 
synergistic or antagonistic effects. From the constructed network, we find that the DDI-related proteins 
for warfarin are metabolism-related (such as CYP2C9, CYP3A4, and CYP1A2) and infer that the warfa-
rin involved DDIs are mainly pharmacokinetic.
Drug Extracted enzyme involved in DDIs Frequency p value
Ibuprofen
PTGS1 protein, human 5 1.20E-05
Cytochrome P-450 CYP2C9 3 7.47E-03
Aryl Hydrocarbon Hydroxylases 3 1.28E-02
Warfarin
CYP3A4 protein, human 13 0
Cytochrome P-450 CYP3A 17 0
Prostaglandin-Endoperoxide Synthases 3 2.32E-11
PTGS2 protein, human 3 2.32E-11
Cyclooxygenase 2 3 3.38E-08
Cytochrome P-450 CYP1A2 5 1.77E-04
Cytochrome P-450 CYP2D6 5 5.10E-04
CYP3A protein, human 5 5.65E-04
Steroid 16-alpha-Hydroxylase 11 4.60E-03
Steroid Hydroxylases 11 7.25E-03
Aryl Hydrocarbon Hydroxylases 77 8.92E-03
CYP2C9 protein, human 67 5.81E-02
Cytochrome P-450 CYP2C9 67 6.08E-02
Alanine Transaminase 3 8.32E-02
Aspartate Aminotransferases 3 8.47E-02
Furosemide
Thromboxane-A Synthase 3 0
Glutathione Transferase 3 1.78E-15
Sertraline
CYP3A protein, human 8 0
Mixed Function Oxygenases 14 0
Cytochrome P-450 Enzyme System 18 0
Cytochrome P-450 CYP3A 8 0
Steroid 16-alpha-Hydroxylase 5 0
Steroid Hydroxylases 5 0
Aryl Hydrocarbon Hydroxylases 8 0
Cytochrome P-450 CYP2D6 9 0
Cytochrome P-450 CYP2C9 4 1.76E-13
CYP2C9 protein, human 4 1.76E-13
Cytochrome P-450 CYP1A2 3 2.82E-12
Cytochrome P-450 CYP2C19 3 4.10E-06
CYP2C19 protein, human 3 4.10E-06
Receptor, Serotonin, 5-HT1A 3 6.95E-03
Table 2.  Significant proteins identified from substances of MEDLINE for ibuprofen, warfarin, 
furosemide and sertraline.
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Discussion
In this paper we presented a novel algorithm to facilitate knowledge discovery of DDIs by exploring exist-
ing high quality information that was manually complied into substances fields in MEDLINE literature. 
By using a random sampling step our method has the advantage of eliminating irrelevant terms, yielding 
a high accuracy compared to ranking strategies based on term frequency and term pair co-occurrence 
without random sampling. In addition, our method appeared to be capable of identifying proteins and 
networks involved in DDIs, shedding light on potential DDI mechanisms. There are many studies for 
MEDLINE data mining. Our study innovates in the following ways:
1. Recently published research has focused on information extraction from abstract. We focus on 
substances terms in MEDLINE databases in this paper. Substance is chosen to investigate DDIs 
because the field of MEDLINE records contains a lot of useful chemical information including 
MeSH chemical and drug terms, protocol terms and non-MeSH rare disease terms from the NIH 
Office of Rare Diseases. The substances terms of MEDLINE records are generally indexed by spe-
cialized personnel, which makes the information more reliable. To our knowledge, no studies have 
been performed to investigate DDIs using substances terms.
2. For four example compounds, the random sampling step in our algorithm yields a higher overall 
identification accuracy than methods done without random sampling or methods based on fre-
quency only.
3. Our algorithms not only identify possible DDI events but also predict the mechanism by which 
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Figure 2. The social network constructed by selected compounds and proteins for ibuprofen (A), 
warfarin (B) furosemide (C) and sertraline (D). The proteins and the compounds are shown in grey and 
white.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:17357 | DOI: 10.1038/srep17357
two (or more) drugs interact. No algorithm is available for identifying the proteins potentially 
involved in DDIs from the MEDLINE database.
In summary, we believe our algorithm will improve the ability of the research community to efficiently 
use large and complex MEDLINE data. As the number of records in the MEDLINE database continues 
to grow, our algorithm will become increasingly vital for DDI studies.
There are some limitations of the proposed algorithm. Information in substances fields is com-
piled manually, some information is inevitably missing and this is an obstacle for higher recall. Some 
low-frequency terms were excluded at the cutoff of 3, which may have resulted in lower recall. However, 
as more and more references are added to MEDLINE, the impact of these factors will be improved in the 
future. In addition, some mechanism-related information can be summarized in the text of the abstract 
of articles. Therefore, a text-mining algorithm will be developed in subsequent research to automate 
extraction of specific information such as, compounds, genes (or proteins) and their associations from 
the Abstract field of MEDLINE records.
A web service, DDIRANK, will be developed implementing the statistical algorithms described in 
this paper. Users will query DDIRANK by drug/compound name and view analyzed information from 
MEDLINE. The service will be freely accessible and support all common Internet browsers. It will be a 
valuable tool for clinical pharmacists and basic scientists to analyze DDIs in a reliable way.
Generally, the DDIRANK system is an implementation of algorithms that extract substances from 
MEDLINE records and then probabilistically score and rank these terms. The DDIRANK system will 
include two components:
1) DDI_extract. The main function of DDI_extract is to extract substances from MEDLINE records. 
Users can submit analysis queries through the web interface by inputting a compound name. The com-
pound name and its synonym will be used to build a query to search MEDLINE database through the 
PubMed search engine. All MEDLINE records containing the queried compound will be downloaded. 
Substances of the retrieved records will then be extracted and stored in a pre-established MySQL data-
base. 2) DDI_substance. The function of DDI_substance is to identify the most reliable DDI-related 
substance information from the DDI_extract using the random-sampling-based approach shown in this 
paper. The p-value can rank the extracted substances and filter the terms that are not related to DDIs.
The web service will be developed following a 3-tier design: users can submit analysis queries through 
the web interface; the queries will be processed using PHP (middle-tier, application server based on 
Apache) against a MySQL relational database (back-end, database server). The result of each query will 
be presented to the user in the web browser or through email. The results of any query can be exported 
to various popular file formats such as CSV and PDF.
Methods
Identification of DDI-related compounds or proteins from substances of MEDLINE. Our pro-
posed algorithm contains the three steps shown in Fig. 3. In the first step, we searched PubMed for the 
name of the drug and downloaded the resulting articles from MEDLINE. The text in the PubMed IDs 
(PMIDs), title, abstract, substances and MeSH terms fields of these articles was extracted, excluding 
those articles that lacked MeSH terms. The remaining articles were separated into two groups: articles 
containing DDI-related MeSH terms (Group A) and articles without DDI-related MeSH terms (Group 
B). Here, DDI-related MeSH terms include ‘drug interactions’, ‘drug agonism’, ‘drug partial agonism’, ‘drug 
Search Drug “D ”
Remove articles  
without MeSHTerms
Extract articles containing 
MeSHTerms related to drug 
interaction 
1. Calculate frequency of substance 
pairs between “D ” and another substance 
2. Calculate empirical p value of each substance pair 
3. Rank substance pairs based on empirical p value 
In Group B (remaining (m-n) articles ),  
sample n articles with replacement 
 randomly for 100 times
Lists of compounds 
interacted with “D ” 
and related proteins 
…
PubMed 
M articles 
m articles 
Group A 
(n articles) n articles n articles n articles 
Figure 3. Workflow of the algorithm. 
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antagonism’, ‘drug inverse agonism’, ‘drug synergism’, ‘food-drug interactions’, and ‘herb-drug interac-
tions’. A list of all the compounds and proteins in the substances field of articles in group A was created. 
From here on we will refer to members of this list as ‘candidates’ and the co-occurrence of a member 
of this list, either a compound or protein, with the queried drug that was searched for on PubMed, as a 
‘term pair’. Then the number of articles that contained a term pair was counted. We set the cutoff value 
of compound pair frequency at 3, meaning that if the frequency of term pairs in group A was less than 
3, the candidate was not considered for further analysis. The value was selected based on the balance 
of accuracy and the numbers of candidates. As shown in Supplementary Figure 1, with the augment of 
cutoff, the area under the curve (AUC) increases, while the number of obtained compounds decreases.
Generally, because the articles in group A have DDI-related Mesh terms, we believed the number of 
compounds and proteins in group A involved in DDIs would naturally be larger than the number of 
DDI-related compounds and proteins in group B. However, the candidate list derived from the first step 
contained false positives that were unrelated to DDIs. Therefore, an important task was the exclusion of 
false positive candidates. In the second step, we compared the number of the term pairs in the substances 
field of group A with the number of the term pairs in the substances field of group B using random sam-
pling analysis. During this step, the number of articles selected from group B was equal to the number of 
articles that had been selected from group A. The number of term pairs in group B was calculated. The 
process was repeated many times (for example, 100 times) to establish the null distribution of the term 
pairs in the articles without DDIs.
In the third step, the p-value for each candidate compound or protein was calculated based on the dis-
tribution identified in step two. Co-occurrences of protein or compound with queried drugs are integers 
and we made the assumption that the co-occurrences followed a normal distribution. The co-occurrences 
of a term pair were set as x0 (in group A), and x1, x2, x3…x100, (100 times in group B) respectively. Null 
hypothesis H of testing was that x0 has the same distribution with {x1, x2, x3…x100}. The p-value was 
defined as the probability for a right tail event under the assumption of H. The formula used to calculate 
the p-value was p = P(x > x0). In practice, there occurred a special situation in the distribution {x1, x2, 
x3…x100} of x1 = x2 = x3 = … = x100 = 0. In this case, p was set to 0 and the larger x0 was, the higher the 
corresponding candidate compound or protein was ranked. Statistical significance level was set to 0.1. 
A p-value less than 0.1 indicated that the number of the term pairs in articles with DDIs (group A) was 
significantly higher than that in articles without DDIs (group B).
Social network analysis. Social network analysis was applied to explore the connections among 
drug pairs and significant protein terms. Social network analysis is a strategy for characterizing net-
worked structures in terms of nodes (compounds or proteins) and edges (interactions) using graph 
theory40. The term pairs whose p-value < 0.1 and corresponding co-occurrence counts ≥ 3 were selected 
to build a network using the package igraph in R. The terms and articles were considered as people and 
groups in a social network. The term-article matrix was then taken as the group membership of people.
Algorithm Validation. We chose four medications, ibuprofen, warfarin, furosemide and sertraline 
to demonstrate the applicability of our method by validating our DDI predictions against a gold stand-
ard. DDI information for these two compounds was collected from LexiComp (http://online.lexi.com), 
Clinical Pharmacology (http://clinicalpharmacology-ip.com), Drug InteractionChecker (http://www.
drugs.com/drug_interactions.php), and Micromedex (http://micromedex.com) databases as a gold stand-
ard for validation. Ibuprofen is considered to be among the safest nonsteroidal anti-inflammatory drug 
with few side effects, however, combining ibuprofen with some medications, such as aspirin increases the 
risk of certain side effects. Warfarin is an anticoagulant used in the treatment of thrombosis. Warfarin 
can have dangerous side effects (for example bleeding) from interacting with certain medicines or even 
with food. Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption. Some of the 
drug interactions with furosemide can potentially lead to hearing loss, extremely low blood pressure, 
or low potassium levels. Sertraline is a selective serotonin reuptake inhibitor commonly used to treat 
anxiety disorders and major depression. Several potential drug interactions with sertraline can cause 
symptoms of serotonin syndrome, which can be very dangerous.
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